Inhibition of vascular smooth muscle G protein-coupled receptor kinase 2 enhances alpha1D-adrenergic receptor constriction.

American Journal of Physiology. Heart and Circulatory Physiology
Heather I CohnAndrea D Eckhart

Abstract

G protein-coupled receptor kinase 2 (GRK2) is a serine/theorinine kinase that phosphorylates and desensitizes agonist-bound G protein-coupled receptors. GRK2 is increased in expression and activity in lymphocytes and vascular smooth muscle (VSM) in human hypertension and animal models of the disease. Inhibition of GRK2 using the carboxyl-terminal portion of the protein (GRK2ct) has been an effective tool to restore compromised beta-adrenergic receptor (AR) function in heart failure and improve outcome. A well-characterized dysfunction in hypertension is attenuation of betaAR-mediated vasodilation. Therefore, we tested the role of inhibition of GRK2 using GRK2ct or VSM-selective GRK2 gene ablation in a renal artery stenosis model of elevated blood pressure (BP) [the two-kidney, one-clip (2K1C) model]. Use of the 2K1C model resulted in a 30% increase in conscious BP, a threefold increase in plasma norepinephrine levels, and a 50% increase in VSM GRK2 mRNA levels. BP remained increased despite VSM-specific GRK2 inhibition by either GRK2 knockout (GRK2KO) or peptide inhibition (GRK2ct). Although betaAR-mediated dilation in vivo and in situ was enhanced, alpha(1)AR-mediated vasoconstriction was also increased. Further pharmacologica...Continue Reading

References

Mar 1, 1966·Toxicology and Applied Pharmacology·J S WattsS Krop
Apr 1, 1995·Trends in Biochemical Sciences·J IngleseR J Lefkowitz
Dec 20, 1994·Proceedings of the National Academy of Sciences of the United States of America·W J KochR J Lefkowitz
Sep 1, 1996·British Journal of Pharmacology·X F DengD R Varma
Apr 1, 1997·Hypertension·P WieselT Pedrazzini
Mar 18, 1997·Proceedings of the National Academy of Sciences of the United States of America·Y DaakaR J Lefkowitz
May 1, 1997·The Journal of Clinical Investigation·R GrosR D Feldman
May 26, 1999·Clinical Pharmacology and Therapeutics·R GrosR D Feldman
Dec 22, 1999·Archives of Medical Research·R Villalobos-Molina, M Ibarra
Jun 22, 2000·Journal of Molecular and Cellular Cardiology·S RohdeS F Steinberg
Sep 12, 2000·Current Hypertension Reports·D B Corry, M L Tuck
Jan 11, 2001·Trends in Cardiovascular Medicine·R B PennJ L Benovic
Jun 16, 2001·American Journal of Physiology. Renal Physiology·M SalomonssonW J Arendshorst
Jul 31, 2001·European Journal of Pharmacology·Y Yamamoto, K Koike
Jan 24, 2002·Nature·Howard A RockmanRobert J Lefkowitz
Feb 16, 2002·Methods : a Companion to Methods in Enzymology·K J Livak, T D Schmittgen
Mar 20, 2002·The Journal of Clinical Investigation·Akito TanoueGozoh Tsujimoto
May 3, 2002·Journal of Human Hypertension·V DeQuattro, D Li
Jul 3, 2002·Proceedings of the National Academy of Sciences of the United States of America·D Gregg Rokosh, Paul C Simpson
Sep 5, 2002·Physiological Genomics·H-B XinM I Kotlikoff
Nov 2, 2002·Hypertension·Janelle R KeysAndrea D Eckhart
Jul 23, 2003·Bioinformatics·Perikles Simon
Oct 2, 2003·Journal of Molecular and Cellular Cardiology·Jason A Petrofski, Walter J Koch
Jan 30, 2004·Recent Progress in Hormone Research·J R Keys, W J Koch
Feb 28, 2004·Trends in Cardiovascular Medicine·R D Feldman, R Gros
Nov 5, 2004·Molecular and Cellular Biochemistry·Walter J Koch
Dec 24, 2004·The Journal of Pharmacology and Experimental Therapeutics·Michelle A UbertiRandy A Hall
Jan 27, 2005·Proceedings of the National Academy of Sciences of the United States of America·Jihee KimRobert J Lefkowitz
Nov 18, 2005·Cardiovascular Research·Petronila PenelaFederico Mayor
Mar 29, 2006·Cellular and Molecular Life Sciences : CMLS·L R Queen, A Ferro
Jun 20, 2006·Trends in Cardiovascular Medicine·Jakob Lerche HansenSøren P Sheikh
Oct 31, 2006·Biochimica Et Biophysica Acta·Graeme Milligan
Nov 28, 2006·Journal of Medicinal Chemistry·Marco PallaviciniErmanno Valoti

❮ Previous
Next ❯

Citations

Mar 28, 2013·High Blood Pressure & Cardiovascular Prevention : the Official Journal of the Italian Society of Hypertension·Gaetano SantulliGuido Iaccarino
Jul 23, 2011·Circulation Research·Stephen L Belmonte, Burns C Blaxall
Oct 19, 2013·The Journal of Clinical Investigation·Verónica RivasPetronila Penela
Apr 16, 2010·Canadian Journal of Physiology and Pharmacology·Natalia Ziolkowski, Ashok K Grover
Nov 19, 2014·Proceedings of the National Academy of Sciences of the United States of America·Gautam SikkaDan E Berkowitz
Jul 9, 2016·Journal of the American Heart Association·Jian YangChunyu Zeng
Jul 2, 2010·British Journal of Pharmacology·Petronila PenelaFederico Mayor
May 15, 2015·American Journal of Physiology. Cell Physiology·Jonathon M WilletsR A John Challiss
Oct 18, 2013·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Deepak A DeshpandeRaymond B Penn
Jan 7, 2015·The Journal of Biological Chemistry·Elena Tutunea-FatanStephen S G Ferguson
Mar 29, 2020·American Journal of Physiology. Heart and Circulatory Physiology·Melissa LieuWalter J Koch
Jan 25, 2011·Journal of Molecular and Cellular Cardiology·Fadia A KamalBurns C Blaxall
Feb 16, 2019·European Journal of Pharmacology·Xiaojiang QinQingshan Li
Sep 10, 2011·Pharmacology & Therapeutics·Eugenia V GurevichVsevolod V Gurevich

❮ Previous
Next ❯

Related Concepts

Related Feeds

Adrenergic Receptors: Trafficking

Adrenergic receptor trafficking is an active physiological process where adrenergic receptors are relocated from one region of the cell to another or from one type of cell to another. Discover the latest research on adrenergic receptor trafficking here.

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.